You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Hexagon Q2’24: Recurring revenue grows
Hexagon suffered from cyclical headwinds in Q2 but also demonstrated strong underlying development with good growth in recurring revenue and improved efficiency. Analyst Pauli Lohi comments on this development and the company’s outlook.
Read the latest report here https://www.inderes.se/research/hexagon-q224-temporary-weakness-creates-opportunity
00:00 Intro
00:14 Q2 Tops and flops
01:40 Hardware sales
02:38 Recurring revenue
03:38 Improving sales mix & cost savings
04:59 New products
06:02 Expectations for 2024
06:54 Long-term outlook
08:24 Valuation & recommendation
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
Titta på alla videor